1932

Abstract

Professional society recommendations to decrease sudden cardiac death in athletes, including eligibility requirements with disqualification for athletes with diagnosed disease as well as preparticipation screening and emergency preparedness, were updated in 2015. The update includes new sections on aortic disease, channelopathies, and sickle cell trait, as well as a change in format from the previous binary yes/no format to the more nuanced and contemporary “class and level of evidence” format. Eighty-four of the 246 recommendations now carry Class II designation—“reasonable,” or “may be considered.” New language in the document emphasizes counseling as part of the decision process. New data on athletes with implantable cardioverter-defibrillators, and on those with long QT syndrome, have led to a change from blanket restriction of competitive sports participation to a Class IIB “may be considered” recommendation.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-041316-090402
2018-01-29
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/med/69/1/annurev-med-041316-090402.html?itemId=/content/journals/10.1146/annurev-med-041316-090402&mimeType=html&fmt=ahah

Literature Cited

  1. Harmon KG, Drezner JA, Wilson MG, Sharma S. 1.  2014. Incidence of sudden cardiac death in athletes: a state-of-the-art review. Heart 100:1227–34 [Google Scholar]
  2. Harmon KG, Asif IM, Klossner D, Drezner JA. 2.  2011. Incidence of sudden cardiac death in National Collegiate Athletic Association athletes. Circulation 123:1594–600 [Google Scholar]
  3. Maron BJ, Doerer JJ, Haas TS. 3.  et al. 2009. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation 119:1085–92 [Google Scholar]
  4. Maron BJ, Zipes DP. 4.  2005. 36th Bethesda Conference: eligibility recommendations for competitive athletes with cardiovascular abnormalities. J. Am. Coll. Cardiol. 45:1313–75 [Google Scholar]
  5. Maron BJ, Zipes DP, Kovacs RJ. 5.  et al. 2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: preamble, principles, and general considerations: a scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e256–61 [Google Scholar]
  6. Field JM, Hazinski MF, Sayre MR. 6.  et al. 2010. Part 1: executive summary. 2010 Am. Heart Assoc. Guidelines. Cardiopulm. Resusc. Emerg. Cardiovasc. Care 122:S640–56Guidelines for emergency preparedness, critical for survival of sudden cardiac arrest. [Google Scholar]
  7. Gibbons RJ, Smith S, Antman E. 7.  et al. 2003. American College of Cardiology/American Heart Association clinical practice guidelines: Part I: Where do they come from?. Circulation 107:2979–86 [Google Scholar]
  8. Barry MJ, Edgman-Levitan S. 8.  2012. Shared decision making—the pinnacle of patient-centered care. N. Engl. J. Med. 366:780–81Outlines ethical underpinnings and basic concept of shared decision making. [Google Scholar]
  9. Walsh MN, Bove AA, Cross RR. 9.  et al. 2012. ACCF 2012 health policy statement on patient-centered care in cardiovascular medicine: a report of the American College of Cardiology Foundation Clinical Quality Committee. J. Am. Coll. Cardiol. 59:2125–43 [Google Scholar]
  10. Levine BD, Baggish AL, Kovacs RJ. 10.  et al. 2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 1: classification of sports: dynamic, static, and impact. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e262–e266 [Google Scholar]
  11. Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ. 11.  2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: the cardiac channelopathies. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e326–e329 [Google Scholar]
  12. Zipes DP, Link MS, Ackerman MJ. 12.  et al. 2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 9: arrhythmias and conduction defects. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e315–25 [Google Scholar]
  13. Johnson JN, Ackerman MJ. 13.  2012. Competitive sports participation in athletes with congenital long QT syndrome. JAMA 308:764–65Retrospective series of athletes with long QT syndrome, no adverse events. First to describe “shared decision making” for athletes with heart disease. [Google Scholar]
  14. Aziz PF, Sweeten T, Vogel RL. 14.  et al. 2015. Sports participation in genotype positive children with long QT syndrome. JACC Clin. Electrophysiol 1:62–70 [Google Scholar]
  15. Ostby SA, Bos JM, Owen HJ. 15.  et al. 2016. Competitive sports participation in patients with catecholaminergic polymorphic ventricular tachycardia. JACC Clin. Electrophysiol. 2:253–62 [Google Scholar]
  16. Roston TM, Vinocur JM, Maginot KR. 16.  et al. 2015. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circulation Arrhythmia Electrophysiol 8:633–42 [Google Scholar]
  17. Sy RW, Gollob MH, Klein GJ. 17.  et al. 2011. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 8:864–71 [Google Scholar]
  18. Link MS, Myerburg RJ, Estes NAM. 18.  2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 12: emergency action plans, resuscitation, cardiopulmonary resuscitation, and automated external defibrillators. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e334–e338 [Google Scholar]
  19. Drezner JA, Toresdahl BG, Rao AL. 19.  et al. 2013. Outcomes from sudden cardiac arrest in US high schools: a 2-year prospective study from the National Registry for AED Use in Sports. Br. J. Sports Med. 47:1179–83 [Google Scholar]
  20. Hainline B, Drezner J, Baggish A. 20.  et al. 2016. Interassociation consensus statement on cardiovascular care of college student-athletes. J. Athletic Train. 51:344–57Guidance from the National Collegiate Athletic Association and American College of Cardiology. [Google Scholar]
  21. Lampert R, Olshansky B, Heidbuchel H. 21.  et al. 2013. Safety of sports for athletes with implantable cardioverter-defibrillators: results of a prospective, multinational registry. Circulation 127:2021–30Prospective series of athletes with ICDs, no adverse events. Among first prospective studies of athletes with heart disease participating in sports. [Google Scholar]
  22. Lampert R, Olshansky B, Heidbuchel H. 22.  et al. 2017. Safety of sports for athletes with implantable cardioverter-defibrillators. Long-term results of a prospective multinational registry. Circulation 135:2310–12 [Google Scholar]
  23. Drezner JA, Ackerman MJ, Anderson J. 23.  et al. 2013. Electrocardiographic interpretation in athletes: the ‘Seattle criteria’. Br. J. Sports Med. 47:122–24 [Google Scholar]
  24. Sharma S, Drezner JA, Baggish A. 24.  et al. 2017. International recommendations for electrocardiographic interpretation in athletes. J. Am. Coll. Cardiol. 69:1057–75Current reference for ECG interpretation in the athlete. [Google Scholar]
  25. Lawless CE, Olshansky B, Washington RL. 25.  et al. 2014. Sports and exercise cardiology in the United States: cardiovascular specialists as members of the athlete healthcare team. J. Am. Coll. Cardiol. 63:1461–72 [Google Scholar]
  26. Cohen MI, Triedman JK, Cannon BC. 26.  et al. 2012. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm 9:1006–24 [Google Scholar]
  27. Braverman AC, Harris KM, Kovacs RJ, Maron BJ. 27.  2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 7: aortic diseases, including Marfan syndrome. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e303–e309 [Google Scholar]
  28. Van Hare GF, Ackerman MJ, Evangelista J-AK. 28.  et al. 2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 4: congenital heart disease. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e281–e291 [Google Scholar]
  29. Maron BJ, Udelson JE, Bonow RO. 29.  et al. 2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e273–80 [Google Scholar]
  30. Harmon KG, Asif IM, Maleszewski JJ. 30.  et al. 2015. Incidence, cause, and comparative frequency of sudden cardiac death in National Collegiate Athletic Association Athletes: a decade in review. Circulation 132:10–19 [Google Scholar]
  31. Finocchiaro G, Papadakis M, Robertus J-L. 31.  et al. 2016. Etiology of sudden death in sports: insights from a United Kingdom regional registry. J. Am. Coll. Cardiol. 67:2108–15 [Google Scholar]
  32. Maron BJ, Shirani J, Poliac L. 32.  et al. 1996. Sudden death in young competitive athletes: clinical, demographic, and pathological profiles. JAMA 276:199–204 [Google Scholar]
  33. Gersh BJ, Maron BJ, Bonow RO. 33.  et al. 2011. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 58:13 [Google Scholar]
  34. Maron BJ, Rowin EJ, Casey SA. 34.  et al. 2015. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J. Am. Coll. Cardiol. 65:1915–28 [Google Scholar]
  35. Ackerman MJ, Priori SG, Willems S. 35.  et al. 2011. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace 13:1077–109 erratum 14:277 [Google Scholar]
  36. Maron BJ, Maron MS, Semsarian C. 36.  2012. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J. Am. Coll. Cardiol. 60:705–15 [Google Scholar]
  37. James CA, Bhonsale A, Tichnell C. 37.  et al. 2013. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J. Am. Coll. Cardiol. 14:1290–97 [Google Scholar]
  38. Thompson PD, Myerburg RJ, Levine BD. 38.  et al. 2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 8: coronary artery disease. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e310–e314 [Google Scholar]
  39. Parker MW, Thompson PD. 39.  2012. Assessment and management of atherosclerosis in the athletic patient. Prog. Cardiovasc. Dis. 54:416–22 [Google Scholar]
  40. Maron BJ, Harris KM, Thompson PD. 40.  et al. 2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 14: sickle cell trait. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e343–e345 [Google Scholar]
  41. Link MS, Mark Estes NA, Maron BJ. 41.  2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 13: commotio cordis. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e339–e342 [Google Scholar]
  42. Maron BJ, Haas TS, Ahluwalia A. 42.  et al. 2013. Increasing survival rate from commotio cordis. Heart Rhythm 10:219–23 [Google Scholar]
  43. Maron BJ, Levine BD, Washington RL. 43.  et al. 2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 2: preparticipation screening for cardiovascular disease in competitive athletes. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e267–e72 [Google Scholar]
  44. Bonow RO, Nishimura RA, Thompson PD, Udelson JE. 44.  2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 5: valvular heart disease. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e292–e297 [Google Scholar]
  45. Black HR, Sica D, Ferdinand K, White WB. 45.  2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 6: hypertension. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e298–e302 [Google Scholar]
  46. Estes NAM, Kovacs RJ, Baggish AL, Myerburg RJ. 46.  2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 11: drugs and performance-enhancing substances. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e330–e333 [Google Scholar]
  47. Mitten MJ, Zipes DP, Maron BJ, Bryant WJ. 47.  2015. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 15: legal aspects of medical eligibility and disqualification recommendations. A scientific statement from the American Heart Association and American College of Cardiology. Circulation 132:e346–e349 [Google Scholar]
/content/journals/10.1146/annurev-med-041316-090402
Loading
/content/journals/10.1146/annurev-med-041316-090402
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error